Market Overview

UPDATE: Benchmark Initiates Omnicell at Buy on Growth and Earnings Visibility

Share:
Related OMCL
Earnings Scheduled For February 15, 2017
7 Biotech And Healthcare Picks For 2017 From Cantor Fitzgerald

Benchmark initiated coverage on Omnicell (NASDAQ: OMCL) with a Buy rating and a $19.00 price target.

Benchmark commented, "We are initiating coverage of Omnicell at Buy with a $19 price target based on an 18x multiple of $1.05 in EPS we forecast this year. Omnicell offers a good mix of visibility from 80% recurring revenue, and attractive 15%-20% forecast earnings growth, in our view. We anticipate long term expanding demand for Omnicell's medication management systems to control costs and improve healthcare quality by automating manual tasks. The 2012 MTS acquisition opens new markets and demonstrates the accretive power of leveraging Omnicell's strong free cash flow."

Omnicell closed at $15.57 on Thursday.

Latest Ratings for OMCL

DateFirmActionFromTo
Jan 2017DoughertyInitiates Coverage OnBuy
Jan 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Sep 2016Sidoti & Co.DowngradesBuyNeutral

View More Analyst Ratings for OMCL
View the Latest Analyst Ratings

Posted-In: BenchmarkAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (OMCL)

View Comments and Join the Discussion!